⚡ Key Takeaways
- 6% of U.S. adults have an ADHD diagnosis and about half received their diagnosis in adulthood, but an estimated 14% of adults remain undiagnosed
- Qelbree (viloxazine) was FDA-approved for adults in 2021 and represents the newest non-stimulant option, with label updates in January 2025 providing better pharmacodynamic data
- Jornay PM is taken at bedtime and releases methylphenidate after a 10-hour delay, providing symptom control when you wake up without morning dosing
- The stimulant shortage began in October 2022 with Adderall and has affected multiple medications due to DEA production caps, not manufacturing issues
- Non-stimulants like Strattera and Qelbree show comparable long-term effectiveness to stimulants for improving executive function and attention when taken consistently
Look, I get the frustration. You’ve finally figured out why concentrating feels impossible, why you can’t remember appointments, why starting tasks feels like pushing a boulder uphill. You get a diagnosis, a prescription, and then your pharmacy tells you it’ll be weeks before your medication arrives.
Or maybe you haven’t been diagnosed yet, but you’re seeing yourself in every ADHD description online. You’re not imagining it. Research shows that 14% of adults have undiagnosed ADHD, with women significantly more likely to slip through the cracks than men.
The good news? The medication landscape has changed dramatically in the last few years. New options have been approved, and the evidence for non-stimulant treatments has gotten much stronger. Even with the ongoing shortages, there are pathways to effective treatment.
The Adult ADHD Diagnosis Gap
Here’s something most people don’t realize. Up to 90% of children with ADHD continue experiencing symptoms into adulthood. But in one study, 75% of adults with ADHD were never diagnosed in childhood. That means the majority of adults with ADHD are walking around without knowing why executive function feels so difficult.
The numbers tell a striking story. An estimated 6% of U.S. adults have an ADHD diagnosis, and about half of those adults received their diagnosis in adulthood. But recent research suggests 14% of adults meet criteria for undiagnosed ADHD, with women disproportionately affected.
Why So Many Adults Go Undiagnosed
In childhood, the male to female ratio of ADHD diagnosis is 4:1. In adults, it’s closer to 1:1. What changed? Not the actual prevalence, just the recognition. Girls often present with inattentive symptoms rather than hyperactive symptoms, which teachers and parents miss. By adulthood, the hyperactivity quiets down, but the executive function challenges remain.
Understanding the Stimulant Shortage
Let’s talk about what’s actually happening with the medication shortage, because the explanations you’ve heard are probably incomplete.
The shortage began in October 2022 with Adderall supply issues. It has since impacted Vyvanse, Ritalin, and their generic equivalents. While some name brands have been removed from the FDA Drug Shortage Database, many generic forms remain in short supply as of 2025.
The Real Cause: DEA Production Caps
Here’s what you need to know. This isn’t primarily a manufacturing problem. Pharmaceutical companies have consistently stated they are producing as much as the DEA permits. The DEA sets annual quotas for controlled substances like amphetamines and methylphenidate, and those caps restrict supply even when demand increases.
The shortage worsened after a surge in adult ADHD diagnoses during the COVID-19 pandemic. Heightened demands on attention and expanded access to telehealth contributed to more adults seeking evaluation. Rather than increasing production caps to meet this demand, the DEA reduced medication availability.
“I’ve been on Adderall for 3 years and suddenly can’t find it anywhere. My pharmacy says it could be months. I have a demanding job and two kids. What am I supposed to do? Just fail at everything until the DEA decides to make more medication available?”
I understand how stressful this is, and you’re not alone. This is affecting hundreds of thousands of patients. The good news is we have options. For some patients, switching to a different stimulant formulation that’s currently available works well. For others, this becomes an opportunity to try non-stimulant medications like Qelbree or Strattera, which aren’t subject to DEA production caps and can be very effective. We can also look at combination approaches or extended-release formulations like Jornay PM that may be more available. Let’s find you a solution that actually works.
What the Shortage Means for Patients
| Medication Class | Current Availability (2025) | Alternative Options |
|---|---|---|
| Adderall (amphetamine salts) | Intermittent shortages, generic limited | Vyvanse, Dexedrine, non-stimulants |
| Vyvanse (lisdexamfetamine) | Improved but still limited | Generic available since patent expiry |
| Ritalin/Concerta (methylphenidate) | Better availability than amphetamines | Multiple formulations, Jornay PM |
| Non-stimulants | Generally available | Not subject to DEA caps |
New 2025 Options: Qelbree and Jornay PM
The ADHD medication landscape has evolved significantly. Two medications deserve particular attention for adults navigating treatment in 2025.
Qelbree (Viloxazine Extended-Release)
Qelbree represents the newest category of non-stimulant ADHD medication. It was FDA-approved for adults in 2021 and for children ages 6-17 in 2020. In January 2025, the FDA approved an updated label with new pharmacodynamic data, providing better understanding of how the medication works.
Viloxazine is a selective norepinephrine reuptake inhibitor. It also has effects on the serotonin 5-HT2C receptor. Unlike older non-stimulants, Qelbree was specifically developed for ADHD rather than repurposed from other uses.
Jornay PM (Methylphenidate Delayed-Release)
Jornay PM takes a completely different approach to stimulant delivery. You take it at bedtime (around 9 PM), and it releases methylphenidate after a delay of about 10 hours. The initial absorption is delayed so that no more than 5% of total drug is available within the first 10 hours after dosing.
After the lag period, absorption occurs with a median time to peak concentration of 14 hours. That means symptom control starts when you wake up, without needing to remember morning medication.
Non-Stimulant Alternatives That Work
For years, stimulants were considered the gold standard for ADHD treatment, with non-stimulants viewed as second-tier options. Recent research has challenged that assumption.
A 2024 meta-analysis published by King’s College London found that chronic use of methylphenidate and atomoxetine (Strattera) have comparable effects for improving executive functions in people with ADHD when taken over longer periods. Both drugs showed their best effect on improving attention.
Strattera (Atomoxetine)
Strattera is a selective norepinephrine reuptake inhibitor that has been available since 2002. It works by increasing norepinephrine availability in the brain, which helps improve attention and reduce hyperactivity and impulsivity.
The effects of Strattera are not immediate. It may take several weeks to reach full potential. For adults who need same-day symptom relief, this can be frustrating. But for those who want consistent 24-hour coverage without the ups and downs of stimulant dosing, Strattera offers real advantages.
| Feature | Strattera (Atomoxetine) | Qelbree (Viloxazine) |
|---|---|---|
| Mechanism | Selective NRI | Selective NRI + 5-HT2C effects |
| Time to effect | 2-4 weeks for full effect | 1-2 weeks for initial effect |
| Dosing schedule | Once or twice daily | Once daily |
| Controlled substance | No | No |
| Adult FDA approval | 2002 | 2021 |
Intuniv (Guanfacine Extended-Release)
Intuniv works through a different mechanism entirely. It’s a central alpha-2 adrenergic receptor agonist that targets the prefrontal cortex, a brain region involved in attention, behavior, and impulse control.
Intuniv is particularly effective for reducing hyperactivity and impulsivity. It’s often used as an adjunct medication for individuals who require additional control of hyperactive and impulsive symptoms, especially in combination with stimulant medication.
“I tried Strattera for 6 weeks and honestly didn’t notice much difference. My doctor wants me to keep trying non-stimulants because of the shortage but I’m worried I’m just wasting time when stimulants actually worked for me before. Do non-stimulants actually work or are they just what doctors prescribe when they can’t get you the real medication?”
Non-stimulants are real medication with solid evidence behind them. That said, individual response varies significantly. Some people respond beautifully to Strattera, others don’t. Six weeks is a reasonable trial, and if you’re not seeing benefit, it’s worth trying a different non-stimulant like Qelbree rather than giving up on the category entirely. The recent research showing equivalent long-term outcomes between methylphenidate and atomoxetine is real. But if you’ve had a clear response to stimulants and can access them, that’s valuable information about what works for your brain.
Stimulants vs Non-Stimulants: What to Expect
The choice between stimulant and non-stimulant ADHD medication isn’t just about availability. These medication classes work differently and feel different.
How Stimulants Work
Stimulant medications like methylphenidate (Ritalin, Concerta, Jornay PM) and amphetamines (Adderall, Vyvanse) increase dopamine and norepinephrine in the brain. The effect is rapid, usually within 30-60 minutes, and you can often feel when the medication is working.
That immediate feedback is both an advantage and a disadvantage. You know quickly if a stimulant is helping. You also notice when it wears off, which can create a rebound effect for some people.
How Non-Stimulants Work
Non-stimulants like Strattera, Qelbree, and Intuniv work more gradually. They build up in your system over days to weeks. You might not notice a specific moment when they “kick in.” Instead, after a few weeks, you realize tasks feel slightly easier or your mind feels less chaotic.
This gradual onset means you need patience. It also means steady, consistent symptom control without the peaks and valleys of stimulant dosing.
| Characteristic | Stimulants | Non-Stimulants |
|---|---|---|
| Time to effect | 30-60 minutes | 1-4 weeks |
| Duration of action | 4-12 hours depending on formulation | 24 hours (consistent levels) |
| Controlled substance | Yes (Schedule II) | No |
| Abuse potential | Yes | Minimal to none |
| Effect on appetite | Often decreased significantly | Minimal to moderate |
| Effect on sleep | Can interfere if taken late | Variable, some cause sedation |
| Cardiovascular monitoring | Required | Required but generally lower risk |
Side Effect Profiles
Stimulants commonly cause decreased appetite, difficulty sleeping if taken too late in the day, increased heart rate and blood pressure, and sometimes anxiety or irritability. These effects are dose-dependent and often improve with formulation changes.
Non-stimulants have different side effect profiles. Strattera and Qelbree can cause nausea (especially when starting), fatigue, decreased appetite, and increased heart rate. Intuniv often causes sedation and low blood pressure, which can be useful for people with hyperactivity but problematic for others.
How to Choose the Right Medication
There’s no single “best” ADHD medication. The right choice depends on your symptom profile, lifestyle, medical history, and individual response.
Factors to Consider
If you need immediate symptom relief for specific situations like work or school, stimulants offer that rapid on-off control. If you want consistent 24-hour coverage without thinking about timing, non-stimulants or long-acting stimulants make more sense.
If you have a history of substance use concerns or work in a profession where controlled substances are problematic, non-stimulants avoid those regulatory hurdles. If you have cardiovascular issues, some medications carry lower risk than others.
If you struggle with morning routine or have executive function challenges around medication adherence, once-daily options or bedtime dosing (Jornay PM) reduce the burden. You can access your medication schedules and appointment reminders through our patient portal. If you’re pregnant or planning pregnancy, treatment options become more limited and require specialized discussion.
Starting Treatment
Most clinicians start with either a long-acting stimulant or a non-stimulant, depending on the factors above. The medication is started at a low dose and gradually increased based on response and side effects.
For stimulants, you’ll usually know within a few days if the dose and formulation are working. For non-stimulants, give it at least 4-6 weeks at an adequate dose before deciding it’s not effective.
Regular follow-up during the first few months is essential. Blood pressure and heart rate monitoring, symptom tracking, and side effect assessment help optimize treatment.
Insurance Coverage and Access
Even when medication is available, insurance coverage creates another barrier. ADHD medications range from inexpensive generic stimulants to costly brand-name non-stimulants.
Cost Considerations
Generic immediate-release stimulants like methylphenidate and amphetamine salts are usually very affordable, often $10-30 per month even without insurance. Extended-release formulations cost more, typically $50-150 for generics.
Brand-name medications like Vyvanse (now with generics available), Qelbree, and Jornay PM can cost $300-400 per month without insurance. Most insurance plans cover these but may require prior authorization or step therapy.
Prior Authorization
Many insurance plans require you to try and fail generic stimulants before approving newer or brand-name options. This “step therapy” makes clinical sense in some cases but can be frustrating when specific formulations work better for your schedule or side effect profile.
Prior authorization for non-stimulants often requires documentation that stimulants were tried and either ineffective or contraindicated. This process can take days to weeks, during which you may be without medication. Dr. Erkut’s patients can track their medication requests and prior authorization status through the secure patient portal.
Patient Assistance Programs
Most pharmaceutical companies offer patient assistance programs for those who can’t afford their medications. Qelbree, Vyvanse, and other brand-name ADHD medications have programs that can significantly reduce or eliminate costs for eligible patients.
What People Are Asking?
Ready to Find the Right ADHD Treatment?
Dr. Erkut provides comprehensive ADHD evaluations and medication management at her Mercer Island practice, helping adults find effective treatment even during the ongoing medication shortages.
BOOK A CONSULTATION
Sources & References
- Staley B. (2024). ADHD in Adults: New Research Highlights Trends and Treatment. American Psychiatric Association. Read more
- Du C, et al. (2025). Prevalence of Undiagnosed Attention Deficit Hyperactivity Disorder in Adults. Health Promotion Research, 13(1). Read more
- King’s College London. (2024). New study finds that both stimulant and non-stimulant medications improve cognition in ADHD. Read more
- American Journal of Managed Care. (2024). US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment. Read more
This content is for informational purposes only and does not constitute medical advice. ADHD medication selection depends on individual factors including symptom profile, medical history, medication availability, and insurance coverage. Never start, stop, or change psychiatric medication without consulting a qualified healthcare provider. Dr. Erkut provides personalized ADHD evaluations to determine the most appropriate treatment for your specific situation.